Nortrilen Use In Pregnancy & Lactation

Pregnancy: Nortriptyline should not be administered during pregnancy unless the expected benefit to the patient outweighs the theoretical risk to the foetus.
Using high dosages of TCAs in the third trimester may result in effects, including neurobehavioral disturbances, in the newborn infant.
Lethargy has been reported in neonates with amitriptyline and urine retention with nortriptyline (metabolite of amitriptyline) administered to pregnant women until date of birth.
Lactation: As nortriptyline is found in breast milk in low concentrations it is not likely to affect the infant when therapeutic doses are used. The dose ingested by the infant is about 2% of the weight-related maternal daily dose (in mg/kg).
Breast-feeding can be continued during nortriptyline therapy if considered of clinical importance but observation of the infant is recommended, particularly in the first 4 weeks after giving birth.
Fertility: No data on the effect of nortriptyline on human and animal fertility is available.